The original synthetic GHRH analog — a 29-amino-acid fragment of Growth Hormone Releasing Hormone with FDA approval history and decades of clinical research as the most studied GHRH analog in medicine.
Sermorelin is a synthetic 29-amino-acid analog corresponding to the first 29 amino acids of natural Growth Hormone Releasing Hormone (GHRH). The natural GHRH molecule is 44 amino acids long, but researchers discovered that the first 29 amino acids contain the complete biological activity for GHRH receptor binding and GH release — the remaining 15 amino acids at the C-terminus are needed for stability but not receptor activation.
Sermorelin (GHRH 1-29) was developed and studied as a pharmaceutical agent, receiving FDA approval as Geref (sermorelin acetate) for the diagnostic evaluation of pituitary function and for the treatment of GH deficiency in children. This made it the first clinically approved GHRH analog. While Geref was later withdrawn from the US market for commercial reasons (not safety concerns), Sermorelin remains one of the most extensively studied GHRH analogs in both clinical and research contexts.
Its long track record, safety data, and well-characterized mechanism make it a reference compound for the broader class of GHRH analogs.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
Sermorelin binds directly to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary. This activates a Gs protein-coupled signaling cascade, increasing intracellular cyclic AMP (cAMP) and ultimately calcium signaling, which triggers the exocytosis of stored growth hormone vesicles. The GH released then travels to the liver and peripheral tissues to stimulate IGF-1 production.
Crucially, the body's natural negative feedback mechanisms remain intact — as GH rises, somatostatin (the GH-inhibiting hormone) is also released, which prevents runaway GH overproduction. This self-regulating feature is one reason Sermorelin is considered a relatively clean research tool for GH axis studies.
The hypothalamus and pituitary are like a two-part walkie-talkie system: the hypothalamus sends GHRH (the "release GH now" message), and the pituitary responds by releasing GH. Sermorelin is a copy of that radio message. Injecting Sermorelin is like transmitting the correct radio signal directly to the pituitary's receiver — the pituitary hears the message and responds normally, releasing GH in its natural pattern, with all the normal feedback controls still operating. Direct GH injection bypasses this entirely — it's like dropping GH canisters from a helicopter and hoping it's the right amount.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Sermorelin has an unusually deep clinical research record for a peptide, including FDA-approved diagnostic use and multiple published human trials dating back to the 1970s and 1980s. The following summarizes parameters as studied and administered in the published literature.
The Geref formulation was supplied as lyophilized sermorelin acetate with diluent. Research protocols reconstitute in bacteriostatic water for injection. Published stability data supports refrigeration (2–8°C) of reconstituted solution. Lyophilized form documented stable at −20°C. Half-life in plasma is approximately 10–20 minutes (rapid enzymatic degradation), which is why bedtime injection was used in research to align with the nocturnal GH pulse.
Daily subcutaneous administration at bedtime was the protocol used in the Merriam et al. adult study (Merriam et al., 2001). This timing rationale — injecting at bedtime to mimic the naturally highest-amplitude nocturnal GH pulse — was explicitly stated in the study methodology. Pediatric therapeutic protocols also used daily bedtime administration to preserve pulsatility while maximizing GH secretion (Thorner et al., 1996).
Key References: Thorner MO et al. (1996). Sermorelin therapy in children with GH deficiency. NEJM. · Merriam GR et al. (2001). Sermorelin in healthy elderly subjects. J Clin Endocrinol Metab. · Walker JL et al. (1990). GHRH stimulation test — diagnostic criteria. J Clin Endocrinol Metab. · Lanes R (1992). Sermorelin vs. GH in GH deficiency. J Pediatr.
Sermorelin was the first synthetic GHRH analog to receive FDA approval — a milestone that established the clinical validity of pituitary stimulation as a therapeutic and diagnostic approach. That happened in the 1980s, making it one of the older members of the modern synthetic peptide era.
The discovery that GHRH(1-29) retains full activity was itself a significant research finding — it showed that the first 29 of 44 amino acids carry all the biological information needed for receptor activation, and the C-terminal portion serves mainly a structural and stability role. This kind of structure-function research is fundamental to modern peptide drug design.
Sermorelin was withdrawn from the US market as Geref in 2008 — not due to safety issues, but because the manufacturer decided to discontinue production of the injectable pediatric formulation. It remains in active research use and continues to be studied in anti-aging and endocrinology research contexts.
Every batch of Sermorelin with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.